Results 1 to 10 of about 7,208 (133)

Ultrastructural skin alterations of healthy subjects with anti-desmoglein 1 antibodies in endemic areas to pemphigus foliaceus: A case series [PDF]

open access: yesJournal of Translational Autoimmunity, 2023
Background: Endemic pemphigus foliaceus and endemic pemphigus vulgaris are autoimmune dermatologic disorders endemic to the Peruvian Amazon. Objective: To determine the ultrastructural skin alterations of three healthy subjects with anti DSG-1 antibodies
Willy Ramos   +10 more
doaj   +2 more sources

Endocytosis of IgG, Desmoglein 1, and Plakoglobin in Pemphigus Foliaceus Patient Skin [PDF]

open access: yesFrontiers in Immunology, 2019
Pemphigus foliaceus (PF) is one of the two main forms of pemphigus and is characterized by circulating IgG to the desmosomal cadherin desmoglein 1 (DSG1) and by subcorneal blistering of the skin.
Dyah A. M. Oktarina   +5 more
doaj   +2 more sources

IgA pemphigus showing IgA antibodies to desmoglein 1 and 3 [PDF]

open access: yesDermatology Practical & Conceptual, 2016
Background: IgA pemphigus is a rare autoimmune vesiculo-pustular skin disease. Only approximately 70 cases have been reported to date. We report a case of IgA pemphigus with IgA antibodies to desmoglein 1 (Dsg1) and desmoglein 3 (Dsg3).
Salama Hegazy   +5 more
doaj   +2 more sources

Hereditary epidermolytic palmoplantar keratosis due to a novel desmoglein‐1 mutation: A case report [PDF]

open access: yesClinical Case Reports
Key Clinical Message Keratosis palmoplantaris striata type I (SPPK‐I) is a rare autosomal‐dominant type of hereditary epidermolytic palmoplantar keratoderma, which can be caused by mutations in desmoglein‐1 (DSG‐1).
Kevin Koschitzki   +8 more
doaj   +2 more sources

Non-COVID-19 Vaccinations and the Induction of Autoantibodies in Pemphigus Diseases: A Review of the Speculative Issue and Our Clinical-Laboratory Experience [PDF]

open access: yesAntibodies
Background: Pemphigus diseases are rare autoimmune blistering disorders mediated by pathogenic autoantibodies directed mainly against desmoglein 1 and desmoglein 3.
Maksymilian Markwitz   +4 more
doaj   +2 more sources

Desmoglein-1 Deficiency Mimicking Omenn Syndrome

open access: yesIndian Journal of Dermatology
Meltem Comert   +6 more
doaj   +2 more sources

Desmoglein autoantibodies and disease severity in pemphigus patients – correlations and discrepancies [PDF]

open access: yesFolia Medica, 2023
Aim: To assess the correlation between the levels of anti-desmoglein-1 and anti-desmoglein-3 autoantibodies and disease severity in pemphigus patients.
Zhaneta H. Zhelyazkova   +4 more
doaj   +3 more sources

Evaluation of desmoglein 1 and desmoglein 3 autoantibodies in oral cancer: A pilot study

open access: yesJournal of Indian Academy of Oral Medicine and Radiology, 2023
Background: Carcinogenesis is a complex multistep process involving alterations at the cellular level. Alteration in cell-to-cell adhesion of oral epithelium plays an important role in carcinogenesis and metastasis.
Pavan Kumar Yellarthi   +4 more
doaj   +1 more source

HLA class II antigens in Croatian patients with pemphigus vulgaris and their correlation with anti-desmoglein antibodies

open access: yesFrontiers in Immunology, 2023
Pemphigus vulgaris (PV) is an acquired autoimmune blistering disease characterized by the production of autoantibodies targeting desmosomal cadherins, primarily desmoglein 1 and desmoglein 3, leading to acantholysis. The etiology of PV is multifactorial,
Ines Lakoš Jukić   +4 more
doaj   +1 more source

TNF receptor–related factor 3 inactivation promotes the development of intrahepatic cholangiocarcinoma through NF‐κB‐inducing kinase–mediated hepatocyte transdifferentiation

open access: yesHepatology, EarlyView., 2022
Abstract Background and Aims Intrahepatic cholangiocarcinoma (ICC) is a deadly but poorly understood disease, and its treatment options are very limited. The aim of this study was to identify the molecular drivers of ICC and search for therapeutic targets.
Yuto Shiode   +16 more
wiley   +1 more source

Home - About - Disclaimer - Privacy